Hand-foot syndrome associated with short infusions of combination chemotherapy with gemcitabine and vinorelbine

Annals of Oncology

Volumn 12, Issue 12, 2001, Pages 1761-1763

  Laack, E ^a   Mende, T ^a   Knuffmann, C ^a   Hossfeld, D K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Chemotherapy; Gemcitabine; Hand foot sydrome; Non small cell lung cancer; Vinorelbine

Indexed keywords

CAPECITABINE; CYTARABINE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; METOCLOPRAMIDE; NAVELBINE; UFT; UREA;

ADULT; ALLERGIC REACTION; ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CASE REPORT; CONTROLLED STUDY; DISEASE ASSOCIATION; ERYTHEMA; FATIGUE; HAND FOOT SYNDROME; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; NAUSEA; PARESTHESIA; PLEURA EFFUSION; PRIORITY JOURNAL; SKIN EXFOLIATION; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DRUG ERUPTIONS; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; VINBLASTINE;

EID: 0035702433     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1013575816870     Document Type: Article

References (24)

1. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study
2. A phase II study of navelbine in the treatment of non-small-cell lung cancer
3. A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated non-small-cell lung cancer
4. Activity of gemcitabine in patients with non-small-cell lung cancer: A multicenter extended phase II study
5. Gemcitabine - A safety review
6. Vinorelbine: An overview
7. The hand-foot syndrome in sickle cell haemoglobinopathy
8. Chemotherapy-associated palmar-plantar erythroydysesthesia syndrome
9. Hand-foot syndrome induced by high dose, short term, continuous 5-fluorouracil infusion
10. Palmar-plantar erthrodysesthesia syndrome associated with 5-fluorouracil treatment
11. Treatment of refractory metastatic breast cancer with 5-fluorouracil and levofolinic acid as 48-hours continous venous infusion
12. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continous-infusion fluorouracil for advanced colorectal cancer: A Spanish Cooperative Group for Therapy (TTD) study
13. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
14. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study
15. Paclitaxel, UFT, and calcium folinate in metastatic breast cancer
16. Palmar-plantar erythrodysesthesia and cytarabine
17. Combination vs. sequential doxorubicin and docetaxel a primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group
18. Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy
19. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy
20. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine
21. Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer
22. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology
23. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: A randomized, double-blind clinical trial using a canine model
24. Topical DSMO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia